Dietrich Elizabeth A, Ong Yee Tsuey, Stovall Janae L, Dean Hansi, Huang Claire Y-H
Arbovirus Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado.
Takeda Vaccines, Inc., Cambridge, Massachusetts.
Am J Trop Med Hyg. 2017 Nov;97(5):1423-1427. doi: 10.4269/ajtmh.17-0185. Epub 2017 Aug 18.
Recombinant live-attenuated chimeric tetravalent dengue vaccine viruses, TDV-1, -2, -3, and -4, contain the premembrane and envelope genes of dengue virus serotypes 1-4 in the replicative background of the attenuated dengue virus type-2 (DENV-2) PDK-53 vaccine strain. Previous results have shown that these recombinant vaccine viruses demonstrate limited infection and dissemination in and are unlikely to be transmitted by the primary mosquito vector of DENVs. In this report, we expand this analysis by assessing vector competence of all four serotypes of the TDV virus in , the secondary mosquito vector of DENVs. Our results indicate that these vaccine viruses demonstrate incompetence or defective infection and dissemination in these mosquitoes and will likely not be transmissible.
重组减毒嵌合四价登革热疫苗病毒TDV-1、-2、-3和-4，在减毒的2型登革热病毒（DENV-2）PDK-53疫苗株的复制背景中，包含1-4型登革热病毒的前膜和包膜基因。先前的结果表明，这些重组疫苗病毒在体内表现出有限的感染和传播，并且不太可能由登革热病毒的主要蚊媒传播。在本报告中，我们通过评估TDV病毒所有四种血清型在登革热病毒的次要蚊媒中的媒介能力，扩展了这一分析。我们的结果表明，这些疫苗病毒在这些蚊子中表现出无媒介能力或有缺陷的感染和传播，并且很可能不会传播。
